How many people inject insulin? UK estimates from 1991 to 2010

Diabetes, Obesity and Metabolism

Volumn 16, Issue 6, 2014, Pages 553-559

  Holden, S E ^a   Gale, E A M ^b   Jenkins Jones, S ^c   Currie, Craig J ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c Global Epidemiology   (United Kingdom)

Author keywords

Cost; Diabetes; Epidemiology; Insulin; Prevalence

Indexed keywords

INSULIN; ORAL ANTIDIABETIC AGENT; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; DIABETIC PATIENT; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PREVALENCE; UNITED KINGDOM; COST BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; ECONOMICS; EPIDEMIOLOGY; FACTUAL DATABASE; INCIDENCE; MIDDLE AGED; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; COST-BENEFIT ANALYSIS; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG PRESCRIPTIONS; FEMALE; GREAT BRITAIN; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; MALE; MIDDLE AGED; PREVALENCE;

EID: 84899630955     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12260     Document Type: Article

References (32)

1. Massó González EL, Johansson S, Wallander MA, Garcia Rodríguez LA. Trends in the prevalence and incidence of diabetes in the UK: 1996-2005. J Epidemiol Community Health 2009; 63: 332-336.
2. Diabetes UK. Diabetes in the UK 2010: key statistics on diabetes. 2010. Available from URL: http://www.diabetes.org.uk/Documents/Reports/Diabetes_in_the_UK_2010.pdf. Accessed 5 October 2012.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
4. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
5. Holden SE, Poole CD, Morgan CL, Currie CJ. Evaluation of the incremental cost to the National Health Service of prescribing analogue insulin. BMJ Open 2011; 1: e000258.
6. The Health and Social Care Information Centre. Prescribing for diabetes in England - 2005-2006 to 2010-2011. 2011. Available from URL: http://www.hscic.gov.uk/pubs/prescribingfordiabetes05-11. Accessed 22 January 2014.
7. CPRD. Clinical Practice Research Datalink. 2012. Available from URL: http://www.cprd.com. Accessed 6 February 2013.
8. Population Estimates Unit. Population estimates quinary age groups for UK constituent countries - mid 1971 to mid 2010. 2011. Available from URL:http://www.ons.gov.uk/ons/rel/pop-estimate/population-estimates-for-uk--england-and-wales--scotland-and-northern-ireland/population-estimates-timeseries-1971-to-current-year/index.html. Accessed 9 October 2012.
9. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998; 17: 857-872.
10. Harvey JN, Craney L, Kelly D. Estimation of the prevalence of diagnosed diabetes from primary care and secondary care source data: comparison of record linkage with capture-recapture analysis. J Epidemiol Community Health 2002; 56: 18-23.
11. Gatling W, Budd S, Walters D, Mullee MA, Goddard JR, Hill RD. Evidence of an increasing prevalence of diagnosed diabetes mellitus in the Poole area from 1983 to 1996. Diabet Med 1998; 15: 1015-1021.
12. Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract 2010; 60: e128-e136.
13. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-1197.
14. Anonymous. Self-monitoring of blood glucose in diabetes. Drug Ther Bull 2007; 45: 65-69.
15. Centers for Disease Control and Prevention (CDC). Number (in millions) of adults with diabetes by diabetes medication status, United States, 1997-2010. 2012. Available from URL: http://www.cdc.gov/diabetes/statistics/meduse/fig1.htm. Accessed 7 September 2012.
16. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963-1972.
17. National Institute for Health and Care Excellence. NICE issues national guidelines for the management of blood glucose levels in people with type 2 diabetes. 2002. Available from URL: http://www.nice.org.uk/guidance/index.jsp?action=article&o=29002. Accessed 13 August 2013.
18. National Institute for Health and Care Excellence. About the Quality Outcomes Framework (QOF). 2013. Available from URL: http://www.nice.org.uk/aboutnice/qof/qof.jsg. Accessed 22 January 2014.
19. European Medicines Agency. European public assessment reports. Available from URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125. Accessed 13 August 2013.
20. Horvath K, Jeitler K, Berghold A et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007; 2: CD005613.
21. Hirsch IB, Bergenstal RM, Parkin CG, Wright E Jr, Buse JB. A real-world approach to insulin therapy in primary care practice. Clin. Diabetes 2005; 23: 78-86.
22. Inzucchi SE, Bergenstal RM, Buse JB et al. American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
23. Primary Care Quality and Outcomes Framework (QOF) Indicator Advisory Committee. Recommendations of the committee's review of the 2009/10 QOF indicator DM23. 2010. Available from URL: http://www.nice.org.uk/nicemedia/live/13081/50074/50074.pdf. Accessed 22 May 2013.
24. Currie CJ, Gale EAM, Poole CD. Estimation of primary care treatment costs and treatment efficacy for people with type 1 and type 2 diabetes in the United Kingdom from 1997 to 2007. Diabet Med 2010; 27: 938-948.
25. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004; 27: 1535-1540.
26. Holden SH, Barnett AH, Peters JR et al. The incidence of type 2 diabetes in the United Kingdom from 1991 to 2010. Diabetes Obes Metab 2013; 15: 844-852.
27. Tierney EJ, Cadwell BL, Engelgau MM et al. Declining mortality rate among people with diabetes in North Dakota, 1997-2002. Diabetes Care 2004; 27: 2723-2725.
28. Dale AC, Vatten LJ, Nilsen TI, Midthjell K, Wiseth R. Secular decline in mortality from coronary heart disease in adults with diabetes mellitus: cohort study. BMJ 2008; 337: 99-102.
29. Lipscombe LL, Hux JE. Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005: a population-based study. Lancet 2007; 369: 750-756.
30. Gregg EW, Gu Q, Cheng YJ, Narayan KM, Cowie CC. Mortality trends in men and women with diabetes, 1971 to 2000. Ann Intern Med 2007; 147: 149-155.
31. Tan HH, McAlpine RR, James P et al. Diagnosis of type 2 diabetes at an older age: effect on mortality in men and women. Diabetes Care 2004; 27: 2797-2799.
32. Lutgers HL, Gerrits EG, Sluiter WJ et al. Life expectancy in a large cohort of type 2 diabetes patients treated in primary care (ZODIAC-10). PLoS One 2009; 4: e6817.